Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth?

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE ... 2 Currently, there are no approved TKIs that inhibit the full spectrum of clinically relevant primary and secondary mutations in KIT.

GSK previously entered into a licensing agreement with CureVac, which granted GSK full rights to develop and manufacture ...